10 September 2018
A new report by visiongain forecasts that overall sales of human vaccines will reach $49.8 billion worldwide in 2020. That revenue growth will continue steadily through to 2026, especially with advances in vaccine technology. That revenue prediction and others appear in Vaccine Sales Analysis 2016-2026: Discover Market Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases. The new study appears in March 2016.
Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand technological and commercial prospects of industries and markets in healthcare and other fields.
Visiongain’s updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of vaccines. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing these vaccines, assessing their potentials from 2016. The human vaccines market holds many commercial opportunities from 2016, including rising sales in developed and emerging countries.
Visiongain predicts that the global vaccines market will continue to grow at a steady pace from 2016 to 2026. That sales expansion will be stimulated by ageing populations and the increasing prevalence of infectious and chronic diseases. Also, with globalisation, demand for travel vaccines will increase. Adding to this will be the rising demand from underdeveloped and rising countries – as their economies improve, their healthcare expenditures rise, benefiting sales of vaccines.
Aanchal Verma, a pharmaceutical industry analyst in visiongain, said: “Vaccinations save billions of dollars each year by avoiding vaccine-preventable infections and reducing the disease and economic burden globally. As the world moves towards an ageing population, the elderly become more susceptible to contracting infections owing to their pre-existing conditions and weaker immune system, thereby boosting the demand for vaccines. Furthermore, high birth rates with poor sanitary conditions, but increasingly improved health care systems and vaccination routines in the emerging markets will greatly fuel demand for vaccines.
“Although the vaccine industry makes up a small segment for pharmaceutical companies, it represents a dynamic and robust growth market. With the increased awareness of the benefits of vaccinations across the world, the demand for immunisation programmes increases. Furthermore, developments in vaccine technology, delivery, efficacy and novel disease targeting will drive the long-term growth of the human vaccines industry.”
Visiongain’s new investigation gives individual revenue predictions to 2026 for four vaccine submarkets at world level:
• Paediatric vaccines
• Adult vaccines
• Elderly vaccines
• Travel vaccines.
That analysis also shows 10 revenue forecasts to 2026 for leading vaccines, including these:
• ProQuad/M-M-R- II/Varivax.
The study also shows prospects for vaccine sales in developed and developing regions, with individual revenue forecasts to 2026 for 11 countries:
• United States (US)
• Germany, France, United Kingdom, Italy and Spain
• Brazil, Russia, India and China.
In particular the analysis explores these six market leaders:
• Merck & Co.
• Johnson & Johnson
Visiongain’s updated report also analyses vaccines in research and development:
• Prophylactic vaccines
• Products for children
• Agents for protecting adults
• Treatments for older people
• Travel vaccination
• Therapeutic vaccines.
Vaccine Sales Analysis 2016-2026: Discover Market Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.